Company profile
Quantum Biopharma Ltd.
NASDAQ:QNTMBiotechnology: Pharmaceutical Preparations
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05821387 | phase1 | completed | 2023-03-22 | 2023-07-29 | Quantum Biopharma | Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers |
| NCT05652907 | phase2 | terminated | 2023-01-19 | 2023-05-24 | Quantum Biopharma | Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) |
| NCT04619706 | phase2 | terminated | 2020-12-14 | 2021-08-24 | Quantum Biopharma | Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19 |
FDA applications (0)
No records yet.